https://beta.crstoday.com/news/sightglass-vision-launches-control-the-contrast-campaign-to-advance-myopia-management-awareness/2486758/daily0.7https://beta.crstoday.com/news/bvi-secures-ce-mark-for-virtuoso-surgical-platform/2486757/daily0.7https://beta.crstoday.com/news/essilorluxottica-partners-with-tfos-to-advance-global-standards-in-ocular-surface-health/2486756/daily0.7https://beta.crstoday.com/news/haag-streit-usa-marco-lombart-sign-exclusive-us-distribution-deal-for-diagnostic-platforms/2486755/daily0.7https://beta.crstoday.com/news/phase-1-data-for-vamikibart-published-in-ijama-ophthalmologyi/2486754/daily0.7https://beta.crstoday.com/news/low-dose-atropine-shows-promise-in-slowing-childhood-myopia-real-world-study-finds/2486753/daily0.7https://beta.crstoday.com/news/meiragtx-announces-the-acquisition-of-xlrp-therapy-from-jj/2486752/daily0.7https://beta.crstoday.com/news/revenio-group-to-acquire-visionix-in-290-million-euro-deal/2486751/daily0.7https://beta.crstoday.com/news/glaukos-highlights-sustainability-progress-in-2025-report/2486750/daily0.7https://beta.crstoday.com/news/glaukos-secures-permanent-j-code-for-epioxa/2486749/daily0.7https://beta.crstoday.com/news/bostonsight-expands-scleral-lens-portfolio-with-new-smaller-diameter-options/2486748/daily0.7https://beta.crstoday.com/news/halma-acquires-surgistar-to-strengthen-ophthalmic-portfolio/2486747/daily0.7https://beta.crstoday.com/news/smoking-doubles-risk-of-major-eye-diseases-global-study-finds/2486746/daily0.7https://beta.crstoday.com/news/onpoint-vision-expands-clinical-trial-for-investigational-lens-targeting-amd-patients/2486745/daily0.7https://beta.crstoday.com/news/atia-vision-reports-positive-36-month-results-for-shape-changing-iol-at-ascrs/2486744/daily0.7https://beta.crstoday.com/news/eclipse-life-sciences-completes-enrollment-in-phase-2-bettis-1-trial-for-ec-104-in-dme/2486743/daily0.7https://beta.crstoday.com/news/outdoor-time-linked-to-lower-myopia-risk-in-children-in-china-large-study-finds/2486742/daily0.7https://beta.crstoday.com/news/forsight-robotics-performs-worlds-first-fully-robot-assisted-cataract-surgery-in-human-patient/2486741/daily0.7https://beta.crstoday.com/news/johnson-johnson-marks-10-million-implants-for-tecnis-eyhance-iol/2486740/daily0.7https://beta.crstoday.com/news/cloudbreak-pharma-launches-new-website-to-support-us-expansion-and-highlight-ophthalmic-pipeline/2486739/daily0.7https://beta.crstoday.com/news/mount-sinai-ophthalmologist-unveils-hospitals-first-in-human-technology-enabling-real-time-outflow-measurement-during-eye-surgery/2486738/daily0.7https://beta.crstoday.com/news/cassini-and-leica-microsystems-collaborate-to-enhance-intraoperative-guidance-for-cataract-surgery/2486737/daily0.7https://beta.crstoday.com/news/new-tecnis-puresee-iol-clinical-data-to-be-presented-at-ascrs-2026/2486736/daily0.7https://beta.crstoday.com/news/lumibird-medical-moves-to-acquire-malaysian-partner-establish-southeast-asia-growth-hub/2486735/daily0.7https://beta.crstoday.com/news/bausch-lomb-receives-fda-clearance-for-advanced-vitrectomy-and-fluidics-technologies/2486734/daily0.7https://beta.crstoday.com/news/oculus-launches-pentacam-cornea-oct-in-us-combining-scheimpflug-and-oct-imaging/2486733/daily0.7https://beta.crstoday.com/news/aurion-biotech-doses-first-patients-in-us-phase-3-trial-of-regenerative-cell-therapy-for-corneal-disease/2486732/daily0.7https://beta.crstoday.com/news/bausch-lomb-launches-envista-envy-iol-in-europe/2486731/daily0.7https://beta.crstoday.com/news/tenpoint-therapeutics-appoints-stephen-s-lane-md-as-chief-medical-officer/2486730/daily0.7https://beta.crstoday.com/news/lenstec-appoints-blake-michaels-as-chief-executive-officer/2486729/daily0.7https://beta.crstoday.com/news/fda-recall-prompts-nationwide-warning-over-millions-of-eye-drops/2486728/daily0.7https://beta.crstoday.com/news/amgen-reports-strong-phase-3-results-for-new-tepezza-delivery-method-in-thyroid-eye-disease/2486727/daily0.7https://beta.crstoday.com/news/alcon-launches-clareon-truplus-enhanced-design-monofocal-and-toric-iols-at-ascrs-2026/2486726/daily0.7https://beta.crstoday.com/news/glaukos-to-showcase-innovative-ophthalmic-technologies-at-ascrs-2026/2486725/daily0.7https://beta.crstoday.com/news/international-study-finds-low-dose-atropine-slows-myopia-progression-across-ethnicities/2486724/daily0.7https://beta.crstoday.com/news/testing-home-based-glaucoma-monitoring-using-melbourne-rapid-fields-mrf/2486723/daily0.7https://beta.crstoday.com/news/national-eye-institute-seeks-public-input-for-2026-2031-strategic-plan/2486722/daily0.7https://beta.crstoday.com/news/luminopia-research-highlights-durable-vision-gains-in-children-with-amblyopia-at-aapos-meeting/2486721/daily0.7https://beta.crstoday.com/news/global-health-leaders-unite-to-combat-avoidable-blindness-in-landmark-partnership/2486720/daily0.7https://beta.crstoday.com/news/zeiss-to-unveil-ai-driven-surgical-and-digital-innovations-at-ascrs-2026/2486719/daily0.7https://beta.crstoday.com/news/luminopia-reports-early-promise-for-digital-therapy-in-treating-pediatric-eye-disorder/2486718/daily0.7https://beta.crstoday.com/news/biogen-to-acquire-apellis-pharmaceuticals-in-56-billion-deal/2486717/daily0.7https://beta.crstoday.com/news/haag-streit-reopens-global-slit-lamp-imaging-competition-for-2026/2486716/daily0.7https://beta.crstoday.com/news/amaros-launches-interventional-glaucoma-network-to-advance-evidence-generation-in-eye-care/2486715/daily0.7https://beta.crstoday.com/news/iantrek-announces-controlled-release-of-allospan-canal-bio-interventional-glaucoma-surgery-platform/2486714/daily0.7https://beta.crstoday.com/news/lenstec-expands-clearview-3-iol-power-range/2486713/daily0.7https://beta.crstoday.com/news/tenpoint-therapeutics-launches-yuvezzi-a-first-of-its-kind-eye-drop-for-presbyopia-in-the-us/2486712/daily0.7https://beta.crstoday.com/news/viridian-reports-positive-phase-3-data-for-subcutaneous-ted-therapy-eyes-regulatory-filing/2486711/daily0.7https://beta.crstoday.com/news/signablok-receives-orphan-drug-designation-from-fda-for-a-first-in-class-trem-1-peptide-inhibitor-for-the-treatment-of-retinopathy-of-prematurity/2486710/daily0.7https://beta.crstoday.com/news/fda-clears-long-bridge-medical-to-initiate-us-pivotal-clinical-study-for-lensone-prosthetic-capsular-bag/2486709/daily0.7https://beta.crstoday.com/news/apotex-expands-canadian-ophthalmology-portfolio-with-health-canadas-approval-of-clobivis/2486708/daily0.7https://beta.crstoday.com/news/hoya-vision-care-accelerates-global-sustainability-ambitions-through-flagship-one-vision-program/2486707/daily0.7https://beta.crstoday.com/news/centre-for-sight-marks-30-years-with-ophthalmology-conference-on-the-future-of-vision-care/2486706/daily0.7https://beta.crstoday.com/news/veongen-to-report-clinical-progress-of-vg801-gene-therapy-at-arvo-2026-annual-meeting/2486705/daily0.7https://beta.crstoday.com/news/cencora-to-expand-retina-consultants-of-america-through-acquisition-of-eyesouth-partners-retina-business/2486704/daily0.7https://beta.crstoday.com/news/eyedaptic-unveils-eye7-smart-glasses-1/2486703/daily0.7https://beta.crstoday.com/news/phase-3-registration-star-study-of-efdamrofusp-alfa-ibi302-meets-primary-endpoint/2486702/daily0.7https://beta.crstoday.com/news/zeiss-expands-ophthalmic-workflow-portfolio-in-canada-with-enhanced-diagnostic-visualization-and-therapeutic-solutions-for-precision-eye-care/2486701/daily0.7https://beta.crstoday.com/news/ocugen-announces-topline-12-month-data-from-phase-2-armada-clinical-trial-evaluating-ocu410-modifier-gene-therapy-for-ga-secondary-to-dry-amd/2486700/daily0.7https://beta.crstoday.com/news/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease/2486699/daily0.7https://beta.crstoday.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486698/daily0.7https://beta.crstoday.com/news/virtualens-launches-vr-monovision-simulation-for-cataract-consultations/2486697/daily0.7https://beta.crstoday.com/news/prevent-blindness-launches-keratoconus-week-new-patient-education-materials/2486696/daily0.7https://beta.crstoday.com/news/bausch-lomb-reports-positive-24-month-us-data-for-elios-in-open-angle-glaucoma/2486695/daily0.7https://beta.crstoday.com/news/aapos-2026-star-data-highlight-syd-101-benefit-in-younger-children/2486694/daily0.7https://beta.crstoday.com/news/artelo-biosciences-enters-clinical-study-agreement-to-evaluate-novel-cannabinoid-therapy-for-glaucoma-1/2486693/daily0.7https://beta.crstoday.com/news/study-finds-glp-1-drugs-linked-to-lower-risk-of-legal-blindness-in-type-2-diabetes/2486692/daily0.7https://beta.crstoday.com/news/first-patients-treated-with-experimental-gene-therapy-gs010-in-france-early-access-program/2486691/daily0.7https://beta.crstoday.com/news/fda-issues-complete-response-letter-for-idebenone-in-lhon/2486690/daily0.7https://beta.crstoday.com/news/okyo-pharma-reports-positive-quality-of-life-findings-for-urcosimod-in-neuropathic-corneal-pain-study/2486689/daily0.7https://beta.crstoday.com/news/glaukos-launches-epioxa-epithelium-on-therapy-for-keratoconus/2486688/daily0.7https://beta.crstoday.com/news/altris-ai-and-captify-take-top-honors-at-2026-vsp-vision-innovation-challenge/2486687/daily0.7https://beta.crstoday.com/news/glaukos-launches-epioxacareconnect-to-streamline-patient-access-to-cross-linking-treatment/2486303/daily0.7https://beta.crstoday.com/news/fda-issues-third-complete-response-letter-to-aldeyra-therapeutics-for-dry-eye-drug-reproxalap/2486302/daily0.7https://beta.crstoday.com/news/china-approves-worlds-first-implantable-device-for-congenital-nystagmus-treatment/2486301/daily0.7https://beta.crstoday.com/news/alcon-and-lensar-agree-to-terminate-merger-agreement/2486300/daily0.7https://beta.crstoday.com/news/kansas-lawmakers-approve-bill-expanding-optometrists-scope-of-practice/2486299/daily0.7https://beta.crstoday.com/news/global-study-links-semaglutide-formulations-to-rare-risk-of-optic-nerve-damage/2486298/daily0.7https://beta.crstoday.com/news/study-links-vitamin-d-deficiency-to-higher-risk-of-dry-eye-disease/2486297/daily0.7https://beta.crstoday.com/news/lenz-therapeutics-files-ema-application-for-presbyopia-eye-drop-vizz/2486296/daily0.7https://beta.crstoday.com/news/spanish-scientists-develop-artificial-cornea-from-fish-scales/2486295/daily0.7https://beta.crstoday.com/news/heru-showcases-pretestpro-vision-diagnostic-tool-at-vision-expo-2026/2486294/daily0.7https://beta.crstoday.com/news/galimedix-achieves-milestone-payment-after-phase-1-success-of-gal-101-for-ga/2486293/daily0.7https://beta.crstoday.com/news/johnson-johnson-announces-fda-approval-of-tecni-puresee-iol-for-cataract-surgery/2486292/daily0.7https://beta.crstoday.com/news/vital-tears-and-brightstar-therapeutics-form-joint-medical-advisory-board/2486291/daily0.7https://beta.crstoday.com/news/aurion-biotech-appoints-marjan-farid-md-as-chair-of-medical-advisory-board/2486290/daily0.7https://beta.crstoday.com/news/edinburgh-biosciences-showcases-light-based-cataract-treatment-platform-at-100-optical-2026/2486289/daily0.7https://beta.crstoday.com/news/american-academy-of-optometry-announces-2026-retina-summit-in-indianapolis/2486288/daily0.7https://beta.crstoday.com/news/spyglass-pharma-reports-positive-12-month-phase-12-results-for-drug-eluting-iol-system/2486287/daily0.7https://beta.crstoday.com/news/qlaris-bio-appoints-fred-guerard-as-president-and-ceo/2486286/daily0.7https://beta.crstoday.com/news/belgian-neurotech-startup-revision-implant-secures-fda-breakthrough-status-for-brain-implant-vision-technology/2486285/daily0.7https://beta.crstoday.com/news/iqvia-report-examines-untapped-potential-of-ophthalmology-biosimilars-in-europe/2486284/daily0.7https://beta.crstoday.com/news/antigua-and-barbuda-to-host-first-global-summit-for-eye-health-in-november-2026/2486283/daily0.7https://beta.crstoday.com/news/cassini-guidance-system-receives-mdr-approval-launches-across-european-union/2486282/daily0.7https://beta.crstoday.com/news/researchers-identify-early-molecular-trigger-in-age-related-cataracts/2486281/daily0.7https://beta.crstoday.com/news/early-blood-sugar-control-may-reduce-risk-of-diabetic-complications-large-uk-study-finds/2486280/daily0.7https://beta.crstoday.com/news/first-zeiss-vision-clinic-launched-in-mexico-city-featuring-integrated-eye-care-model/2486279/daily0.7https://beta.crstoday.com/news/cirrus-therapeutics-expands-to-singapore-and-unveils-novel-rpe-cell-therapy-program/2486278/daily0.7https://beta.crstoday.com/news/harrow-announces-fda-clearance-of-ind-application-for-phase-3-trial-of-triesence-in-post-cataract-surgery-inflammation-and-pain/2486277/daily0.7https://beta.crstoday.com/news/international-scientific-symposium-on-ophthalmic-imaging-2026-to-convene-global-experts-in-singapore/2486276/daily0.7https://beta.crstoday.com/news/sheraz-daya-awarded-prestigious-iirsi-gold-medal-for-outstanding-contribution-to-ophthalmology/2486275/daily0.7https://beta.crstoday.com/news/rayner-acquires-us-distribution-rights-to-ophthalmic-viscosurgical-device-anikavisc/2486274/daily0.7https://beta.crstoday.com/news/norway-based-circio-reports-up-to-50-fold-increase-in-aav-gene-expression-with-circvec-platform-expands-into-ophthalmology/2486273/daily0.7https://beta.crstoday.com/news/international-ophthalmology-study-sheds-light-on-myopia-biometry-ahead-of-refractive-surgery/2486272/daily0.7https://beta.crstoday.com/news/opus-genetics-supplemental-nda-for-presbyopia-treatment-accepted-by-fda/2486271/daily0.7https://beta.crstoday.com/news/new-study-suggests-indoor-visual-habits-may-be-driving-myopia-surge/2486270/daily0.7https://beta.crstoday.com/news/nicox-highlights-ncx-470-phase-3-data-at-the-american-glaucoma-society-annual-meeting/2486269/daily0.7https://beta.crstoday.com/news/teclens-initiates-first-in-human-trial-of-noninvasive-vision-correction-platform/2486268/daily0.7https://beta.crstoday.com/news/zeiss-launches-collaborative-care-platform-to-enhance-connected-ophthalmic-care/2486267/daily0.7https://beta.crstoday.com/news/defeye-announces-publication-of-two-peer-reviewed-studies-highlighting-biovance-3l-ocular/2486266/daily0.7https://beta.crstoday.com/news/oertli-launches-os-4-up-surgical-platform-in-europe/2486265/daily0.7https://beta.crstoday.com/news/vyome-announces-positive-preclinical-data-for-vt-1908-as-potential-new-treatment-for-uveitis-globally/2486264/daily0.7https://beta.crstoday.com/news/study-global-vision-loss-trends-show-progress-in-some-areas-but-persisting-challenges-in-east-asia/2486263/daily0.7https://beta.crstoday.com/news/eir-biopharma-files-for-17-million-ipo-to-advance-preclinical-eye-disease-pipeline/2486262/daily0.7https://beta.crstoday.com/news/ascrs-foundation-names-drs-aravind-haripriya-and-rengaraj-venkatesh-as-2026-chang-crandall-humanitarian-award-recipients/2486261/daily0.7https://beta.crstoday.com/news/fda-officially-shifts-to-one-trial-standard-for-new-drug-approvals/2486260/daily0.7https://beta.crstoday.com/news/uk-based-axol-bioscience-acquires-newcells-ophthalmology-business/2486259/daily0.7https://beta.crstoday.com/news/harrow-launches-pharmapack-direct-to-prescriber-kits-for-ophthalmic-medications/2486258/daily0.7https://beta.crstoday.com/news/new-study-reveals-how-myopia-alters-eye-coordination-and-pupil-responses/2486257/daily0.7https://beta.crstoday.com/news/eyepoint-appoints-michael-campbell-as-chief-commercial-officer/2486256/daily0.7https://beta.crstoday.com/news/staar-surgical-secures-fda-approval-to-expand-evo-icl-age-indication-to-21-60-years/2486255/daily0.7https://beta.crstoday.com/news/lkc-technologies-provider-of-visual-electroretinography-acquired-by-ametek/2486254/daily0.7https://beta.crstoday.com/news/bostonsight-announces-leadership-changes-to-advance-ocular-surface-care-worldwide/2486253/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-announces-positive-phase-3-sol-1-results-demonstrating-superiority-of-axpaxli-in-wet-amd/2486252/daily0.7https://beta.crstoday.com/news/chla-researchers-advance-eye-cancer-care-with-liquid-biopsy-test/2486251/daily0.7https://beta.crstoday.com/news/fda-provides-feedback-ahead-of-ncx-470-nda-submission/2486250/daily0.7https://beta.crstoday.com/news/eye-pcr-receives-ce-mark-for-fixoflex-endocapsular-device-plans-european-launch/2486249/daily0.7https://beta.crstoday.com/news/nordic-pharma-announces-european-launch-of-lacrifill-canalicular-gel/2486248/daily0.7https://beta.crstoday.com/news/who-urges-faster-action-to-expand-access-to-cataract-surgery-worldwide/2486247/daily0.7https://beta.crstoday.com/news/new-european-study-finds-active-childhood-myopia-control-can-reduce-lifetime-costs-and-vision-burden/2486246/daily0.7https://beta.crstoday.com/news/iveena-doses-first-participant-in-phase-1-trial-of-ivmed-85-for-myopia-progression/2486245/daily0.7https://beta.crstoday.com/news/nih-researchers-create-first-digital-twin-of-critical-eye-cells-opening-new-pathways-for-vision-disease-therapies/2486244/daily0.7https://beta.crstoday.com/news/first-patient-treated-in-france-for-revise-study-evaluating-gs010-gene-therapy-for-nd4-lhon/2486243/daily0.7https://beta.crstoday.com/news/nicox-to-present-phase-3-ncx-470-data-at-2026-american-glaucoma-society-annual-meeting/2486242/daily0.7https://beta.crstoday.com/news/bvi-announces-first-us-implantations-of-fda-approved-finevision-hp-trifocal-iol/2486241/daily0.7https://beta.crstoday.com/news/4dmt-completes-enrollment-for-4d-150-clinical-trial/2486240/daily0.7https://beta.crstoday.com/news/gbl-and-cvc-to-invest-in-rayner-to-support-growth/2486239/daily0.7https://beta.crstoday.com/news/hoya-presents-new-data-on-miyosmart-iq-spectacle-lenses/2486238/daily0.7https://beta.crstoday.com/news/global-study-examines-orthokeratology-lenses-and-childhood-myopia-progression/2486237/daily0.7https://beta.crstoday.com/news/international-study-shows-large-language-models-now-excel-on-ophthalmology-specialty-exams-but-risks-remain/2486236/daily0.7https://beta.crstoday.com/news/haag-streit-announces-biometry-focus-month-2026-webinar-series-in-march/2486235/daily0.7https://beta.crstoday.com/news/arctic-vision-to-acquire-mdco-technologys-ophthalmic-device-business/2486234/daily0.7https://beta.crstoday.com/news/chinas-nmpa-approves-zeiss-artevo-750-and-artevo-850-ophthalmic-microscopes/2486233/daily0.7https://beta.crstoday.com/news/rayner-launches-new-ai-powered-platform-to-improve-patient-understanding-in-ophthalmology/2486232/daily0.7https://beta.crstoday.com/news/staar-surgical-appoints-warren-foust-and-deborah-andrews-as-interim-co-ceos/2486231/daily0.7https://beta.crstoday.com/news/new-study-links-sleeping-posture-with-higher-eye-pressure-in-glaucoma-patients/2486230/daily0.7https://beta.crstoday.com/news/okyo-pharma-reports-successful-fda-meeting-to-support-phase-2b3-development-of-urcosimod-for-neuropathic-corneal-pain/2486229/daily0.7https://beta.crstoday.com/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia/2486228/daily0.7https://beta.crstoday.com/news/centre-for-sight-launches-eye-health-mot-to-support-early-detection-and-long-term-vision-care/2486227/daily0.7https://beta.crstoday.com/news/fda-approves-repeat-treatment-labeling-for-glaukos-idose-tr-in-glaucoma/2486226/daily0.7https://beta.crstoday.com/news/myra-vision-enrolls-first-patient-in-adapt-clinical-study-of-calibreye-adjustable-glaucoma-shunt/2486225/daily0.7https://beta.crstoday.com/news/orasis-pharmaceuticals-presents-new-data-showing-qlosi-is-pupil-selective-in-presbyopic-eyes/2486224/daily0.7https://beta.crstoday.com/news/novaliq-receives-fda-clearance-to-advance-steroid-free-eye-drop-for-inner-eye-inflammation/2486223/daily0.7https://beta.crstoday.com/news/nidek-introduces-phantom-open-field-refraction-system/2486222/daily0.7https://beta.crstoday.com/news/uk-glaucoma-cases-set-to-exceed-16-million-by-2060-study-finds/2486221/daily0.7https://beta.crstoday.com/news/prevent-blindness-issues-statement-on-proposaed-legislation-that-includes-a-2m-cut-to-the-cdcs-vision-health-initiative/2486220/daily0.7https://beta.crstoday.com/news/biotissue-completes-sale-of-surgical-and-wound-care-business-to-biostem-technologies/2486219/daily0.7https://beta.crstoday.com/news/bayer-and-bluerock-therapeutics-investigational-cell-therapy-receives-fda-orphan-drug-designation-for-rp/2486218/daily0.7https://beta.crstoday.com/news/tickets-and-sponsorships-available-for-2026-prevent-blindness-person-of-vision-award-gala-honoring-jim-mcgrann/2486217/daily0.7https://beta.crstoday.com/news/spyglass-pharma-randomizes-first-patients-in-phase-3-trials-of-bim-iol-system-for-glaucoma/2486216/daily0.7https://beta.crstoday.com/news/bioage-labs-expands-bge-102-program-into-ophthalmology-with-planned-study-in-dme/2486215/daily0.7https://beta.crstoday.com/news/spyglass-pharma-files-for-100-million-ipo/2486214/daily0.7https://beta.crstoday.com/news/bvi-announces-leadership-transition/2486213/daily0.7https://beta.crstoday.com/news/newton-and-abb-labs-enter-partnership-to-expand-access-for-independent-optometry/2486212/daily0.7https://beta.crstoday.com/news/lenstec-uk-and-voptica-announce-partnership-to-expand-access-to-artiols-in-the-uk/2486211/daily0.7https://beta.crstoday.com/news/emmecell-appoints-ramin-valian-as-chief-executive-officer/2486210/daily0.7https://beta.crstoday.com/news/international-review-highlights-advances-and-challenges-in-less-invasive-keratoconus-treatment/2486209/daily0.7https://beta.crstoday.com/news/new-study-shows-foundation-ai-models-closing-the-gap-with-doctors-but-multimodal-challenges-remain/2486208/daily0.7https://beta.crstoday.com/news/lenz-therapeutics-launches-make-it-vizzable-campaign-featuring-sarah-jessica-parker-as-brand-ambassador/2486207/daily0.7https://beta.crstoday.com/news/rayner-secures-fda-510k-clearance-for-sophi-phacoemulsification-system/2486206/daily0.7https://beta.crstoday.com/news/orbis-international-appoints-kathleen-sherwin-as-new-president-and-ceo/2486205/daily0.7https://beta.crstoday.com/news/aptargroup-highlights-new-beat-the-blink-technology/2486204/daily0.7https://beta.crstoday.com/news/topcon-healthcare-and-remonihealth-announce-strategic-partnership-to-advance-remote-eye-care/2486203/daily0.7https://beta.crstoday.com/news/allotex-secures-conditional-fda-ide-approval-to-launch-us-clinical-study-for-presbyopia-solution/2486202/daily0.7https://beta.crstoday.com/news/moorfields-study-shows-common-eye-injection-can-restore-vision-in-hypotony/2486201/daily0.7https://beta.crstoday.com/news/nanodropper-now-operating-as-mu-medical-under-new-consolidation-plan/2486200/daily0.7https://beta.crstoday.com/news/annexon-submits-european-marketing-application-for-first-targeted-treatment-for-guillain-barre-syndrome/2486199/daily0.7https://beta.crstoday.com/news/ray-therapeutics-appoints-scott-braunstein-md-as-chairman-of-board-of-directors/2486198/daily0.7https://beta.crstoday.com/news/ikarovec-and-vectorbuilder-enter-exclusive-option-agreement-to-advance-gene-therapy-for-intermediate-amd/2486197/daily0.7https://beta.crstoday.com/news/nanoscope-therapeutics-secures-new-us-patent-for-multi-characteristic-opsin-platform/2486196/daily0.7https://beta.crstoday.com/news/fda-clears-first-daily-disposable-soft-contact-lens-using-edof-technology-for-presbyopia/2486195/daily0.7https://beta.crstoday.com/news/staar-surgical-to-remain-independent-after-shareholders-reject-alcon-merger/2486194/daily0.7https://beta.crstoday.com/news/christopher-j-rapuano-md-begins-term-as-2026-president-of-the-aao/2486193/daily0.7https://beta.crstoday.com/news/okyo-pharma-names-robert-j-dempsey-ceo/2486192/daily0.7https://beta.crstoday.com/news/new-international-myopia-guidance-urges-early-personalized-care/2486191/daily0.7https://beta.crstoday.com/news/new-evidence-links-semaglutide-and-tirzepatide-to-rare-optic-nerve-disorders-in-type-2-diabetes-patients/2486190/daily0.7https://beta.crstoday.com/news/global-study-charts-myopia-risk-in-children-across-asia-and-the-west/2486189/daily0.7https://beta.crstoday.com/news/new-dual-level-visual-field-model-enhances-prediction-of-glaucoma-progression/2486188/daily0.7https://beta.crstoday.com/news/bascom-palmer-eye-institute-abu-dhabi-and-emirates-society-of-ophthalmology-sign-partnership-agreement/2486187/daily0.7https://beta.crstoday.com/news/viridian-therapeutics-veligrotug-bla-accepted-by-fda-with-priority-review-for-thyroid-eye-disease-ted/2486186/daily0.7https://beta.crstoday.com/news/spanish-study-shows-combining-atropine-and-dims-spectacle-lenses-improves-myopia-control-in-children/2486185/daily0.7https://beta.crstoday.com/news/wspos-releases-statement-in-support-of-low-dose-atropine-for-treatment-of-myopia/2486184/daily0.7https://beta.crstoday.com/news/eaglet-eye-and-ovitz-form-strategic-partnership-to-introduce-xwave-aberrometer-to-europe/2486183/daily0.7https://beta.crstoday.com/news/new-study-highlights-tiny-vesicles-with-big-potential-for-corneal-disease-treatment/2486182/daily0.7https://beta.crstoday.com/news/fda-extends-action-date-for-aldeyras-reproxalap-nda-review/2486181/daily0.7https://beta.crstoday.com/news/rinsada-signs-exclusive-distribution-agreement-with-eye-drop-shop-to-expand-across-canada/2486180/daily0.7https://beta.crstoday.com/news/nicox-completes-key-data-package-to-support-ncx-470-nda-submissions-in-the-us-and-china/2486179/daily0.7https://beta.crstoday.com/news/core-releases-contact-lens-update-spotlighting-tfos-dews-iii-dry-eye-report/2486178/daily0.7https://beta.crstoday.com/news/essilorluxottica-expands-european-footprint-with-acquisition-of-belgian-ophthalmology-platform-signifeye/2486177/daily0.7https://beta.crstoday.com/news/zeiss-celebrates-100-years-of-operation-in-the-us/2486176/daily0.7https://beta.crstoday.com/news/centre-for-sight-performs-first-envista-envy-iol-implantation-in-england/2486175/daily0.7https://beta.crstoday.com/news/study-evaluates-therapeutic-impact-of-amblyoplay-in-pediatric-anisometropic-amblyopia/2486174/daily0.7https://beta.crstoday.com/news/azura-ophthalmics-receives-fda-feedback-supporting-planned-nda-submission-for-azr-md-001/2486173/daily0.7https://beta.crstoday.com/news/ocumetics-announces-enhancements-to-lens-delivery-system-following-first-in-human-procedures/2486172/daily0.7https://beta.crstoday.com/news/prevent-blindness-statement-on-impacts-of-expiring-tax-credits-for-aca-marketplace-health-insurance-plans/2486171/daily0.7https://beta.crstoday.com/news/navigate-expands-medical-advisory-board-to-accelerate-growth/2486170/daily0.7https://beta.crstoday.com/news/eyeyon-medical-secures-fda-ide-approval-to-launch-us-clinical-study-of-endoart-synthetic-endothelial-layer/2486169/daily0.7https://beta.crstoday.com/news/seabelife-and-unither-pharmaceuticals-forge-pact-to-advance-novel-retinal-therapy-toward-clinical-trials/2486168/daily0.7https://beta.crstoday.com/news/temporary-retinal-silencing-restores-vision-in-adult-mice-with-amblyopia-mit-study-finds/2486167/daily0.7https://beta.crstoday.com/news/zeiss-completes-acquisition-of-brighten-optix-advancing-global-myopia-management-strategy/2486166/daily0.7https://beta.crstoday.com/news/johnson-johnson-partners-with-naomi-watts-to-spotlight-vision-as-essential-to-healthy-aging/2486165/daily0.7https://beta.crstoday.com/news/fda-approves-amneal-pharmaceuticals-generic-version-of-restasis/2486164/daily0.7https://beta.crstoday.com/news/new-study-links-glaucomatous-visual-field-loss-to-impaired-driving-performance-and-higher-crash-risk/2486163/daily0.7https://beta.crstoday.com/news/vialase-treats-first-patient-in-us-ide-clinical-trial-for-incision-free-femtosecond-laser-glaucoma-procedure/2486162/daily0.7https://beta.crstoday.com/news/first-patient-implanted-with-avisis-visiplate-glaucoma-treatment-device-in-the-sapphire-trial/2486161/daily0.7https://beta.crstoday.com/news/meibum-scientific-appoints-ryan-s-bleeks-as-interim-ceo/2486160/daily0.7https://beta.crstoday.com/news/essilorluxottica-launches-scientific-advisory-committee-to-accelerate-innovation-across-life-sciences/2486159/daily0.7https://beta.crstoday.com/news/new-ai-dataset-aims-to-transform-eye-care-worldwide/2486158/daily0.7https://beta.crstoday.com/news/study-reveals-longer-gaps-in-glaucoma-care-linked-to-increased-risk-of-blindness/2486157/daily0.7https://beta.crstoday.com/news/access-to-eye-care-improving-across-us-despite-fewer-ophthalmologists-new-study-finds/2486156/daily0.7https://beta.crstoday.com/news/ripple-therapeutics-enters-collaboration-with-bausch-lomb/2486155/daily0.7https://beta.crstoday.com/news/x-cel-specialty-contacts-and-essilor-custom-contacts-announce-in-house-us-manufacturing-of-rose-k-lenses/2486154/daily0.7https://beta.crstoday.com/news/precise-bio-achieves-worlds-first-3d-bio-printed-corneal-implant/2486153/daily0.7https://beta.crstoday.com/news/vision-impairment-associated-with-food-insecurity-in-us-children/2486152/daily0.7https://beta.crstoday.com/news/prevent-blindness-names-matt-macdonald-as-board-of-directors-chair-adds-three-new-members/2486151/daily0.7https://beta.crstoday.com/news/hoya-vision-care-issues-call-to-action/2486150/daily0.7https://beta.crstoday.com/news/newton-partners-with-hong-kong-optical-lens/2486149/daily0.7https://beta.crstoday.com/news/the-vision-council-discusses-tariffs-with-us-trade-representatives/2486148/daily0.7https://beta.crstoday.com/news/eyepoint-announces-positive-recommendation-for-pivotal-phase-3-trials-for-duravyu/2486147/daily0.7https://beta.crstoday.com/news/harrow-completes-acquisition-of-melt-pharmaceuticals/2486146/daily0.7https://beta.crstoday.com/news/topcon-announces-fda-510k-clearance-and-us-launch-of-omnia-a-fully-automated-4-in-1-pretesting-system/2486145/daily0.7https://beta.crstoday.com/news/tearoptix-secures-strategic-financing-and-announces-formation-of-scientific-advisory-board/2486144/daily0.7https://beta.crstoday.com/news/heidelberg-engineering-joins-ccoi-as-part-of-essilorluxotticas-vision-architect-membership/2486143/daily0.7https://beta.crstoday.com/news/bausch-lomb-outlines-ambitious-new-chapter-for-growth-at-investor-day-event/2486142/daily0.7https://beta.crstoday.com/news/heru-surpasses-one-million-eyes-tested-with-wearable-platform/2486141/daily0.7https://beta.crstoday.com/news/essilorluxottica-joins-global-collaborative-community-of-ophthalmic-innovation/2486140/daily0.7https://beta.crstoday.com/news/orasis-launches-qlosi-starter-packs-to-expand-access-and-support-demand-for-presbyopia-treatment/2486139/daily0.7https://beta.crstoday.com/news/ior-partners-launches-mdod-collaboration-model-1/2486138/daily0.7https://beta.crstoday.com/news/cartwheel-signs-loi-to-license-clearsight-therapeutics-over-the-counter-pink-eye-treatment/2486137/daily0.7https://beta.crstoday.com/news/eli-lilly-makes-another-ophthalmic-acquisition-after-gaining-rights-to-meiragtxs-gene-therapy-program-for-lca4/2486136/daily0.7https://beta.crstoday.com/news/spyglass-pharma-announces-results-from-two-clinical-trials-of-its-bim-iol-system-for-glaucoma-and-ocular-hypertension/2486135/daily0.7https://beta.crstoday.com/news/bls-one-by-one-recycling-program-diverts-over-691000-pounds-of-eye-care-waste-from-us-landfills/2486134/daily0.7https://beta.crstoday.com/news/the-vision-council-foundation-begins-season-of-giving-to-support-future-opticians/2486133/daily0.7https://beta.crstoday.com/news/advancing-sight-network-and-miracles-in-sight-announce-merger/2486132/daily0.7https://beta.crstoday.com/news/newton-acquires-founders-optical/2486131/daily0.7https://beta.crstoday.com/news/4d-molecular-therapeutics-reports-positive-long-term-phase-12-prism-data-in-wet-amd/2486130/daily0.7https://beta.crstoday.com/news/santen-receives-uk-approval-for-ryjunea-to-slow-childhood-myopia-progression/2486129/daily0.7https://beta.crstoday.com/news/polyactiva-raresight-announce-collaboration-for-rare-pediatric-retinal-diseases/2486128/daily0.7https://beta.crstoday.com/news/defeye-announces-exsight-ventures-investment-to-accelerate-ocular-biologics/2486127/daily0.7https://beta.crstoday.com/news/lambdavision-advances-space-manufactured-artificial-retina/2486126/daily0.7https://beta.crstoday.com/news/nanoscope-reports-long-term-data-for-its-optogenetic-therapy-in-retinitis-pigmentosa/2486125/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-achieves-randomization-target-in-sol-r-trial/2486123/daily0.7https://beta.crstoday.com/news/aavantgarde-closes-141-million-series-b-financing/2486122/daily0.7https://beta.crstoday.com/news/sydnexis-announces-topline-pivotal-data-from-phase-3-star-trial-of-syd-101-for-patients-with-pediatric-progressive-myopia/2486124/daily0.7https://beta.crstoday.com/news/prevent-blindness-launches-online-patient-resource-on-insurance-benefits-for-eye-care/2484307/daily0.7https://beta.crstoday.com/news/exploring-a-connection-between-glp-1-drugs-and-vision-loss/2484306/daily0.7https://beta.crstoday.com/news/avisi-technologies-announces-positive-12-month-clinical-data-on-visiplate-aqueous-shunt/2484305/daily0.7https://beta.crstoday.com/news/duke-eye-center-implants-cell-based-therapy-for-mactel/2484304/daily0.7https://beta.crstoday.com/news/viridian-submits-bla-for-veligrotug-in-thyroid-eye-disease/2484303/daily0.7https://beta.crstoday.com/news/everest-medicines-expands-into-ophthalmology-with-licensing-agreement-for-retinal-disease-candidate-in-asia/2484302/daily0.7https://beta.crstoday.com/news/4dmt-and-otsuka-announce-strategic-partnership-to-advance-4d-150-gene-therapy-across-asia-pacific/2484301/daily0.7https://beta.crstoday.com/news/celularity-enters-strategic-partnership-with-defeye-to-advance-regenerative-therapies-in-eye-care/2484300/daily0.7https://beta.crstoday.com/news/oculis-prices-110-million-financing-to-accelerate-privosegtor-development/2484298/daily0.7https://beta.crstoday.com/news/novartis-announces-positive-phase-3-results-for-ianalumab-in-sjogrens-disease/2484297/daily0.7https://beta.crstoday.com/news/eyederm-cosmetics-launches-three-new-beauty-products-for-the-eye/2484296/daily0.7https://beta.crstoday.com/news/the-vision-council-urges-commerce-department-to-exclude-optical-products-from-potential-tariffs/2484295/daily0.7https://beta.crstoday.com/news/ophthalmic-world-leaders-owl-names-first-md-president-and-other-leadership-changes-for-2026/2484293/daily0.7https://beta.crstoday.com/news/locus-biosciences-announces-collaboration-with-viatris-to-develop-antibacterial-therapies-for-ophthalmic-infections/2484292/daily0.7https://beta.crstoday.com/news/smartlens-secures-52-million-to-advance-fda-clearance-and-commercial-launch-of-milens/2484291/daily0.7https://beta.crstoday.com/news/nextgen-healthcare-expands-eye-care-solutions-through-strategic-alignment-with-eyefinity/2484213/daily0.7https://beta.crstoday.com/news/eli-lilly-enters-ophthalmology-sector-with-acquisition-of-adverum-biotechnologies/2484212/daily0.7https://beta.crstoday.com/news/fda-does-not-approve-sydnexis-syd-101-in-pediatric-myopia/2484210/daily0.7https://beta.crstoday.com/news/onesight-essilorluxottica-foundation-and-vision-to-learn-extend-partnership-to-expand-vision-care-for-children-nationwide/2484209/daily0.7https://beta.crstoday.com/news/sanro-health-secures-investment-from-topcon-to-advance-ophthalmic-data-interoperability-and-ai-powered-care/2486121/daily0.7https://beta.crstoday.com/news/ophthalmic-world-leaders-owl-announces-2025-leadership-award-honorees/2484206/daily0.7https://beta.crstoday.com/news/holland-foundation-for-sight-restoration-launches-light-after-darkness-fundraising-campaign/2484205/daily0.7https://beta.crstoday.com/news/bausch-lombs-surgical-planning-software-eyetelligence-now-fully-commercially-available-in-us/2484204/daily0.7https://beta.crstoday.com/news/veo-ophthalmics-announces-us-launch-of-visionone-vr-visual-field-platform/2484203/daily0.7https://beta.crstoday.com/news/topcon-healthcare-launches-idhea-to-advance-digital-research-in-eye-care-and-oculomics/2484202/daily0.7https://beta.crstoday.com/news/lumenis-launches-digital-duet-20-sltyag-platform/2484200/daily0.7https://beta.crstoday.com/news/stoke-therapeutics-presents-2-year-data-from-falcon-study-in-autosomal-dominant-optic-atrophy/2486120/daily0.7https://beta.crstoday.com/news/fda-approves-glaukos-epioxa-as-first-incision-free-corneal-cross-linking-therapy-for-keratoconus/2484198/daily0.7https://beta.crstoday.com/news/aao-office-based-cataract-surgery-study-shows-success-with-minimal-oral-sedation/2484197/daily0.7https://beta.crstoday.com/news/aurion-announces-positive-12-month-results-from-phase-12-clara-trial-of-aurn001-corneal-endothelial-cell-therapy/2484196/daily0.7https://beta.crstoday.com/news/artificial-intelligence-guided-glaucoma-screening-shows-promise/2484195/daily0.7https://beta.crstoday.com/news/haag-streit-usa-unveils-metis-3d-digital-heads-up-module-at-aao-2025/2484194/daily0.7https://beta.crstoday.com/news/sight-sciences-announces-fee-schedule-establishment-for-tearcare-dry-eye-procedure/2484193/daily0.7https://beta.crstoday.com/news/big-data-research-presented-at-aao-2025-drives-new-insights-in-patient-care/2484192/daily0.7https://beta.crstoday.com/news/virtual-vision-health-expands-virtual-eye-platform-with-new-diagnostic-modules-and-multi-exam-integration/2484191/daily0.7https://beta.crstoday.com/news/fda-selects-dompe-for-national-priority-voucher-program-to-accelerate-development-of-novel-intranasal-therapy/2484190/daily0.7https://beta.crstoday.com/news/topcon-healthcare-signs-definitive-agreement-to-acquire-toku-inc/2484189/daily0.7https://beta.crstoday.com/news/nordic-pharma-showcases-lacrifill-canalicular-gel-and-new-clinical-data-at-aao/2486119/daily0.7https://beta.crstoday.com/news/eyecare-partners-to-present-new-research-at-aao/2484188/daily0.7https://beta.crstoday.com/news/heru-surpasses-one-million-eyes-tested-on-its-ai-powered-wearable-vision-diagnostics-platform/2484185/daily0.7https://beta.crstoday.com/news/yora-vision-and-eyexora-global-partner-with-seri-to-advance-new-migs-platform-for-glaucoma/2484184/daily0.7https://beta.crstoday.com/news/essilorluxottica-acquires-retinai-maker-of-ai-and-data-management-technology/2484183/daily0.7https://beta.crstoday.com/news/avisi-technologies-receives-fda-approval-to-study-novel-approach-to-glaucoma-treatment/2484182/daily0.7https://beta.crstoday.com/news/ocusciences-secures-eu-ce-clearance-for-ocumet-beacon-expands-european-deployment/2484181/daily0.7https://beta.crstoday.com/news/iantrek-announces-us-commercial-launch-of-alloflo-uveo-first-surgical-treatment-targeting-the-uveoscleral-pathway/2484180/daily0.7https://beta.crstoday.com/news/spyglass-pharma-announces-promising-24-month-interim-results-from-first-in-human-trial-of-bim-iol-system/2484179/daily0.7